logo

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Tyra Biosciences ( NASDAQ:TYRA )

  3 weeks ago   
post image
On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial ( mUC ) cancer from its ongoing SURF301 Phase 1/2 study. These data will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Ticker Sentiment Impact
TYRA
Neutral
81 %
CRYPTO:DLT
Neutral
10 %
CRYPTO:DCR
Neutral
10 %